Table 1.
SiRNA/miRNA Cancer therapeutics in clinical trials.
| Drug | Target | Disease | Company | Stage |
|---|---|---|---|---|
| SiRNA Cancer therapeutics in clinical trials | ||||
| CALAA-01 | M2 subunit of ribonucleotide | Solid tumors | Calando Pharmaceuticals | Ongoing Phase I, Not recruiting |
| ALN-VSP02 | VEGF and KSP | Solid tumors involving the liver | Alnylam Pharmaceuticals | Completed Phase I |
| Atu027 | Protein Kinase 3 (PKN3) | Solid tumors | Silence Therapeutics AG | Completed Phase I |
| TKM 080301 | Polo-like kinase 1 | Solid tumors | Tekmira Pharmaceutical | Recruiting Phase I |
| siG12D LODER | KRAS | Pancreatic ductal adenocarcinoma | Silenseed Ltd | Phase II, Not yet open |
| siRNA-EphA2-DOPC | EPHA2 | Solid tumors | M.D. Anderson Cancer Center | Phase I, not yet open |
| MiRNA Cancer therapeutics in clinical trials | ||||
| MRX34 | miR-34 mimic | Liver cancer or metastatic cancer with liver involvement | Mirna Therapeutic, Inc. | Recruiting Phase I |